<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T23:15:46Z</responseDate><request verb="GetRecord" identifier="oai:uwspace.uwaterloo.ca:10012/22535" metadataPrefix="dim">https://dspacemainprd01.lib.uwaterloo.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:uwspace.uwaterloo.ca:10012/22535</identifier><datestamp>2025-11-06T08:02:16Z</datestamp><setSpec>com_10012_9936</setSpec><setSpec>com_10012_1</setSpec><setSpec>col_10012_9947</setSpec><setSpec>col_10012_6</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Aborig, Mohamed</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2025-09-23T13:19:07Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2025-09-23T13:19:07Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2025-09-23</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted">2025-09-08</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/10012/22535</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Theranostic gold nanoparticles (GNPs) were engineered to enhance external-beam radiotherapy for prostate cancer while enabling quantitative imaging readouts. I synthesized biocompatible, polyphenol-functionalized GNPs using epigallocatechin gallate (EGCG-GNPs) and curcumin (Curc-GNPs), optimized for colloidal stability, cell-receptor affinity, and antioxidative properties. Comprehensive physicochemical characterization (DLS/ζ-potential, TEM, UV–Vis) and analytical assays (HPLC for drug loading; ICP-MS for Au quantification) established reproducible formulations. In vitro studies in PC-3 cells demonstrated efficient cellular uptake and radiosensitization, evidenced by reduced clonogenic survival compared with radiation alone. In vivo, murine and canine models were used to evaluate biodistribution, acute/sub-acute toxicity, and imaging. Computed-tomography (CT) phantom and tissue studies confirmed a linear relationship between Hounsfield units and gold concentration, enabling noninvasive estimation of intraprostatic nanoparticle burden. A physiologically based pharmacokinetic (PBPK) model captured organ kinetics and supported translation of exposure–response. Finally, I piloted an image-guided intra-arterial delivery paradigm adapted from prostatic arterial embolization: nanoparticle infusion into prostate lobes followed by embolization to promote local retention, reduce systemic exposure, and potentiate radiation dose deposition. This minimally invasive procedure was tested in 3 lab beagles and 1 clinical canine case with naturally occurring prostate cancer. Collectively, these data establish a dual-functional GNP platform that couples CT-visible quantification with meaningful radiosensitization, laying the preclinical and procedural groundwork for image-guided nanoparticle-augmented radiotherapy in prostate cancer.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en</dim:field>
   <dim:field mdschema="dc" element="publisher" lang="en">University of Waterloo</dim:field>
   <dim:field mdschema="dc" element="title">Theranostic Gold Nanoparticles for Enhanced Prostate Cancer Radiotherapy</dim:field>
   <dim:field mdschema="dc" element="type">Doctoral Thesis</dim:field>
   <dim:field mdschema="dc" element="pending">false</dim:field>
   <dim:field mdschema="uws-etd" element="degree" qualifier="department">School of Pharmacy</dim:field>
   <dim:field mdschema="uws-etd" element="degree" qualifier="discipline">Pharmacy</dim:field>
   <dim:field mdschema="uws-etd" element="degree" qualifier="grantor" lang="en">University of Waterloo</dim:field>
   <dim:field mdschema="uws-etd" element="degree">Doctor of Philosophy</dim:field>
   <dim:field mdschema="uws-etd" element="embargo" qualifier="terms">0</dim:field>
   <dim:field mdschema="uws" element="contributor" qualifier="advisor">Wettig, Shawn</dim:field>
   <dim:field mdschema="uws" element="contributor" qualifier="affiliation1">Faculty of Science</dim:field>
   <dim:field mdschema="uws" element="published" qualifier="city" lang="en">Waterloo</dim:field>
   <dim:field mdschema="uws" element="published" qualifier="country" lang="en">Canada</dim:field>
   <dim:field mdschema="uws" element="published" qualifier="province" lang="en">Ontario</dim:field>
   <dim:field mdschema="uws" element="typeOfResource" lang="en">Text</dim:field>
   <dim:field mdschema="uws" element="peerReviewStatus" lang="en">Unreviewed</dim:field>
   <dim:field mdschema="uws" element="scholarLevel" lang="en">Graduate</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>